24 January 2018 EMA/145053/2018 Human Medicines Evaluation Division

List of nationally authorised medicinal products

Active substance: alteplase

Procedure no.: PSUSA/00000112/201705

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5525 Send a question via our website www.ema.europa.eu/contact

An agency of the European Union

© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged.

Product Name (in authorisation

MRP/DCP

National Authorisation

MAH of product in the

Member State where

country)

Authorisation number

Number

member state

product is authorised

Actilyse 50 mg Polvere e solvente per soluzione iniettabile e per infusione Actilyse pó e solvente para solução injetável e perfusão Actilyse 20 mg polvere e solvente per soluzione iniettabile e per infusione Actilyse pulver och vätska till injektions- / infusionsvätska, lösning 10 mg, 20 mg och 50 mg Actilyse injektio- / infuusiokuivaaine ja liuotin, liuosta varten Actilyse injektio- / infuusiokuivaaine ja liuotin, liuosta varten Actilyse 20 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung/Infusionslösung Actilyse 50 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung/Infusionslösung Actilyse 20 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung/Infusionslösung Actilyse 50 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung/Infusionslösung Actilyse 10 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung/Infusionslösung Actilyse 10 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung/Infusionslösung ACTILYSE® Pulver und Lösungsmittel zur Herstellung einer Injektions- bzw. Infusionslösung

DE/H/0015/004

026533048

BOEHRINGER INGELHEIM ITALIA S.P.A.

IT

DE/H/0015/004

8734301

PT

DE/H/0015/004

026533051

BOEHRINGER INGELHEIM, UNIPESSOAL, LDA. BOEHRINGER INGELHEIM ITALIA S.P.A.

DE/H/0015/004

9969

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

FI

DE/H/0015/004

9969

FI

DE/H/0015/004

9969

DE/H/0015/004

BE140332

BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM INTERNATIONAL GMBH SCS BOEHRINGER INGELHEIM COMM.V.

DE/H/0015/004

2000055878

SCS BOEHRINGER INGELHEIM COMM.V.

LU

DE/H/0015/004

2000055879

SCS BOEHRINGER INGELHEIM COMM.V.

LU

DE/H/0015/004

BE 140323

SCS BOEHRINGER INGELHEIM COMM.V.

BE

DE/H/0015/004

BE154341

SCS BOEHRINGER INGELHEIM COMM.V.

BE

DE/H/0015/004

2000055880

SCS BOEHRINGER INGELHEIM COMM.V.

LU

DE/H/0015/004

42414.00.00

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

DE

List of nationally authorised medicinal products EMA/145053/2018

IT

FI BE

Page 2/7

Product Name (in authorisation

MRP/DCP

National Authorisation

MAH of product in the

Member State where

country)

Authorisation number

Number

member state

product is authorised

ACTILYSE ® - PULVER UND LÖSUNGSMITTEL ZUR HERSTELLUNG EINER INJEKTIONSODER INFUSIONSLÖSUNG Actilyse® - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung Actilyse® - Pulver und Lösungsmittel zur Herstellung einer Injektions- oder Infusionslösung Actilyse® Pulver und Lösungsmittel zur Herstellung einer Injektionsbzw. Infusionslösung Actilyse® Pulver und Lösungsmittel zur Herstellung einer Injektionsbzw. Infusionslösung Actilyse, polvo y disolvente para solución inyectable y para perfusión Actilyse, polvo y disolvente para solución inyectable y para perfusión Actilyse, polvo y disolvente para solución inyectable y para perfusión ACTILYSE poudre et solvant pour solution injectable et perfusion ACTILYSE poudre et solvant pour solution injectable et perfusion ACTILYSE poudre et solvant pour solution injectable et perfusion Actilyse 20 mg poudre et solvant pour solution injectable/perfusion Actilyse 20 mg poeder en oplosmiddel voor oplossing voor injectie/infusie Actilyse 50 mg powder and solvent for solution for injection and infusion

DE/H/0015/004

1-24717

BOEHRINGER INGELHEIM RCV GMBH & CO KG

AT

DE/H/0015/004

1-24717

BOEHRINGER INGELHEIM RCV GMBH & CO KG

AT

DE/H/0015/004

1-24717

BOEHRINGER INGELHEIM RCV GMBH & CO KG

AT

DE/H/0015/004

42414.00.00

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

DE

DE/H/0015/004

42414.00.00

BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

DE

DE/H/0015/004

59.494

ES

DE/H/0015/004

59.494

DE/H/0015/004

59.494

DE/H/0015/004

34009 558 529 3 3

DE/H/0015/004

34009 557 184 2 0

DE/H/0015/004

34009 558 530 1 5

DE/H/0015/004

BE 140332

DE/H/0015/004

BE 140332

BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM FRANCE S.A.S BOEHRINGER INGELHEIM FRANCE S.A.S BOEHRINGER INGELHEIM FRANCE S.A.S SCS BOEHRINGER INGELHEIM COMM.V. SCS BOEHRINGER INGELHEIM COMM.V.

DE/H/0015/004

PA 7/43/2

BOEHRINGER INGELHEIM LTD.

IE

List of nationally authorised medicinal products EMA/145053/2018

ES ES FR FR FR BE BE

Page 3/7

Product Name (in authorisation

MRP/DCP

National Authorisation

MAH of product in the

Member State where

country)

Authorisation number

Number

member state

product is authorised

Actilyse 50 mg poudre et solvant pour solution injectable/perfusion Actilyse 50 mg poeder en oplosmiddel voor oplossing voor injectie/infusie Actilyse pó e solvente para solução injetável e perfusão Actilyse, pulver og solvens til injektions- og infusionsvæske, opløsning 50 mg Actilyse Pulver och vätska till injektions- /infusionsvätska, lösning Actilyse 50 mg poudre et solvant pour solution injectable/perfusion Actilyse 50 mg Powder and solvent for solution for injection and infusion Actilyse 50 mg, poeder en oplosmiddel voor oplossing voor injectie en infusie Actilyse, pulver og solvens til injektions- og infusionsvæske, opløsning 20 mg Actilyse 20 mg poudre et solvant pour solution injectable/perfusion Actilyse Pulver och vätska till injektions- /infusionsvätska, lösning Actilyse 20 mg Powder and solvent for solution for injection and infusion Actilyse 10 mg poudre et solvant pour solution injectable/perfusion Actilyse 10 mg poudre et solvant pour solution injectable/perfusion

DE/H/0015/004

BE 140323

BE

DE/H/0015/004

BE140323

SCS BOEHRINGER INGELHEIM COMM.V. SCS BOEHRINGER INGELHEIM COMM.V.

DE/H/0015/004

8734319

PT

DE/H/0015/004

14159

BOEHRINGER INGELHEIM, UNIPESSOAL, LDA. BOEHRINGER INGELHEIM INTERNATIONAL GMBH

DE/H/0015/004

11137

SE

DE/H/0015/004

2000055878

DE/H/0015/004

PL 00015/0120

BOEHRINGER INGELHEIM INTERNATIONAL GMBH SCS BOEHRINGER INGELHEIM COMM.V. BOEHRINGER INGELHEIM LTD.

DE/H/0015/004

RVG 12248

BOEHRINGER INGELHEIM B.V.

NL

DE/H/0015/004

14159

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

DK

DE/H/0015/004

2000055879

LU

DE/H/0015/004

11137

DE/H/0015/004

PL 00015/0120

SCS BOEHRINGER INGELHEIM COMM.V. BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM LTD.

DE/H/0015/004

2000055880

LU

DE/H/0015/004

BE154341

SCS BOEHRINGER INGELHEIM COMM.V. SCS BOEHRINGER INGELHEIM COMM.V.

List of nationally authorised medicinal products EMA/145053/2018

BE

DK

LU UK

SE UK

BE

Page 4/7

Product Name (in authorisation

MRP/DCP

National Authorisation

MAH of product in the

Member State where

country)

Authorisation number

Number

member state

product is authorised

Actilyse 10 mg poeder en oplosmiddel voor oplossing voor injectie/infusie Actilyse 20 mg powder and solvent for solution for injection and infusion Actilyse 20 mg poeder en oplosmiddel voor oplossing voor injectie en infusie Actilyse injektio- / infuusiokuivaaine ja liuotin, liuosta varten Actilyse injektio- / infuusiokuivaaine ja liuotin, liuosta varten Actilyse Pulver och vätska till injektions- /infusionsvätska, lösning Actilyse pó e solvente para solução injetável e perfusão ACTILYSE 10 mg Powder and solvent for solution for injection and infusion Actilyse 10 mg powder and solvent for solution for injection and infusion Actilyse 10 mg, poeder en oplosmiddel voor oplossing voor injectie en infusie Actilyse injektio- / infuusiokuivaaine ja liuotin, liuosta varten Actilyse 50mg κόνις και διαλύτης για ενέσιμο διάλυμα ή διάλυμα για έγχυση Actilyse 20mg κόνις και διαλύτης για ενέσιμο διάλυμα ή διάλυμα για έγχυση

DE/H/0015/004

BE154341

SCS BOEHRINGER INGELHEIM COMM.V.

BE

DE/H/0015/004

PA 7/43/1

BOEHRINGER INGELHEIM LTD.

IE

DE/H/0015/004

RVG 12247

BOEHRINGER INGELHEIM B.V.

NL

DE/H/0015/004

9969

FI

DE/H/0015/004

9969

DE/H/0015/004

11137

DE/H/0015/004

2275881

DE/H/0015/004

PL 00015/0120

BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM, UNIPESSOAL, LDA. BOEHRINGER INGELHEIM LTD.

DE/H/0015/004

PA 7/43/3

BOEHRINGER INGELHEIM LTD.

IE

DE/H/0015/004

RVG 15228

BOEHRINGER INGELHEIM B.V.

NL

DE/H/0015/004

9969

FI

DE/H/0015/004

40886/16-5-2016

BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM ELLAS AE

DE/H/0015/004

60405/13/16-5-2016

BOEHRINGER INGELHEIM ELLAS AE

GR

List of nationally authorised medicinal products EMA/145053/2018

FI SE PT UK

GR

Page 5/7

Product Name (in authorisation

MRP/DCP

National Authorisation

MAH of product in the

Member State where

country)

Authorisation number

Number

member state

product is authorised

Actilyse 10mg κόνις και διαλύτης για ενέσιμο διάλυμα ή διάλυμα για έγχυση Actilyse, pulver og solvens til injektions- og infusionsvæske, opløsning 10 mg Actilyse® Cathflo® 2 mg - Pulver zur Herstellung einer Injektionslösung Actilyse Cathflo 2 mg Pulver zur Herstellung einer Injektions- bzw. Infusionslösung Actilyse Cathflo 2 mg poudre pour solution injectable et perfusion ACTILYSE 2 mg, poudre pour solution injectable et perfusion Actilyse Cathflo 2 mg, polvo para solución inyectable y para perfusión Actilyse 2 mg injektio- / infuusiokuiva-aine liuosta varten Actilyse 2 mg pulver till injektions/infusionsvätska, lösning Actilyse Cathflo 2mg pó para solução para solução injetável e perfusão Actilyse Cathflo 2 mg powder for solution for injection and infusion Actilyse® Cathflo® 2 mg Pulver zur Herstellung einer Injektions- bzw. Infusionslösung Actilyse Cathflo 2 mg poudre et solvant pour solution injectable et perfusion Actilyse Cathflo 2 mg, poeder voor oplossing voor injectie en infusie

DE/H/0015/004

40887/16-5-2016

BOEHRINGER INGELHEIM ELLAS AE

GR

DE/H/0015/004

14159

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

DK

DE/H/0015/005

2-00380

BOEHRINGER INGELHEIM RCV GMBH & CO KG

AT

DE/H/0015/005

2009040300

SCS BOEHRINGER INGELHEIM COMM.V.

LU

DE/H/0015/005

2009040300

LU

DE/H/0015/005

34009 574 194 2 4

DE/H/0015/005

76.900

DE/H/0015/005

32898

DE/H/0015/005

32898

DE/H/0015/005

5143029

SCS BOEHRINGER INGELHEIM COMM.V. BOEHRINGER INGELHEIM FRANCE S.A.S BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM INTERNATIONAL GMBH BOEHRINGER INGELHEIM, UNIPESSOAL, LDA.

DE/H/0015/005

PA 7/43/5

IE

DE/H/0015/005

79189.00.00

BOEHRINGER INGELHEIM LTD. BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

DE/H/0015/005

0632/09040300

SCS BOEHRINGER INGELHEIM COMM.V.

LU

DE/H/0015/005

RVG 103374

BOEHRINGER INGELHEIM B.V.

NL

List of nationally authorised medicinal products EMA/145053/2018

FR ES FI FI PT

DE

Page 6/7

Product Name (in authorisation

MRP/DCP

National Authorisation

MAH of product in the

Member State where

country)

Authorisation number

Number

member state

product is authorised

Actilyse Cathflo 2 mg κόνις για διάλυμα για ένεση ή έγχυση Actilyse Cathflo 2 mg powder for solution for injection and infusion Actilyse 2 mg pulver till injektions/infusionsvätska, lösning Actilyse Cathflo 2 mg Pulver zur Herstellung einer Injektions- bzw. Infusionslösung Actilyse Cathflo 2 mg poudre pour solution injectable et perfusion Actilyse Cathflo 2 mg poeder voor oplossing voor injectie en infusie

DE/H/0015/005

60403/13/16-5-2016

GR

DE/H/0015/005

PL 00015/0325

DE/H/0015/005

44422

DE/H/0015/005

BE330425

BOEHRINGER INGELHEIM ELLAS AE BOEHRINGER INGELHEIM LTD. BOEHRINGER INGELHEIM INTERNATIONAL GMBH SCS BOEHRINGER INGELHEIM COMM.V.

DE/H/0015/005

BE330425

BE

DE/H/0015/005

BE330425

SCS BOEHRINGER INGELHEIM COMM.V. SCS BOEHRINGER INGELHEIM COMM.V.

List of nationally authorised medicinal products EMA/145053/2018

UK SE BE

BE

Page 7/7

PSUSA/00000112/201705 - European Medicines Agency - Europa EU

Jan 24, 2018 - MAH of product in the member state. Member State where product is authorised. Actilyse 50 mg Polvere e solvente per soluzione iniettabile e per infusione. DE/H/0015/004. 026533048. BOEHRINGER INGELHEIM. ITALIA S.P.A.. IT. Actilyse pó e solvente para solução injetável e perfusão. DE/H/0015/004.

133KB Sizes 0 Downloads 106 Views

Recommend Documents

Agenda - European Medicines Agency - Europa EU
Jul 7, 2017 - COMMUNITY MARKETING AUTHORISATIONS AND EXTENSIONS. 2.1. Opinions ... Quality. Rapp: E. Werner .... solutions table with EMA and CVMP responses to the recommendations made by the FishMed Plus. Coalition ...

May 2016 - European Medicines Agency - Europa EU
Jun 22, 2016 - Information Management Division ... This document provides current information related to the volume and evaluation of .... Plasma master file.

Eleclazine - European Medicines Agency - Europa EU
Feb 9, 2017 - Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply).

July 2017 - European Medicines Agency - Europa EU
Jul 5, 2017 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

July 2016 - European Medicines Agency - Europa EU
Jul 4, 2016 - Send a question via our website www.ema.europa.eu/contact ... non-proprietary names (INN) and therapeutic areas for all new ... also available in the monthly reports of the Committee for Orphan Medicinal Products (COMP).

SME Office - European Medicines Agency - Europa EU
maximises the chances of a successful marketing authorisation. ... marketing authorisation. • inclusion in the public SME ... E-mail [email protected]. Website ...

Agenda - European Medicines Agency - Europa EU
Jun 19, 2017 - and may also vary during the course of the review. ...... ViiV Healthcare UK Limited; Treatment of Human Immunodeficiency Virus ..... adjunctive administration of brivaracetam, Treatment of paediatric patients with partial.

Action plan - European Medicines Agency - Europa EU
5 days ago - Guidelines should include more details on the principles of good information design in which content and layout are ... relevance and importance of the QRD template is also acknowledged in this respect as it is the main tool .... databas

Agenda - European Medicines Agency - Europa EU
Jun 15, 2016 - Agenda - EMA Human Scientific Committees' Working. Parties with Healthcare Professionals' Organisations. (HCPWP) meeting. 15 June 2016, 08:45hrs to 10:30hrs – meeting room: 3E. Chairs: I. Moulon (EMA) and Gonzalo Calvo (HCPWP). 15 Ju

Agenda - European Medicines Agency - Europa EU
Jun 26, 2018 - oxadiazole-3-carboximidamide - EMEA-002072-PIP01-16-M01 . ..... Human alpha-galactosidase A - Orphan - EMEA-001828-PIP01-15-M01 .

Agenda - European Medicines Agency - Europa EU
Jul 16, 2018 - Cladribine, EMA/OD/087/17 Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8. 2.2.6. - EMA/OD/098/18. Treatment of ...

SPOR - European Medicines Agency - Europa EU
Feb 7, 2017 - Add an existing Tag to a specific Term . ...... This service creates an email body (text/html) of a user's notification data, a notification is based on.

ATMP - European Medicines Agency - Europa EU
Nov 24, 2017 - E8. 09/08/2017. 10/08/2017. 24/08/2017 17/08/2017 22/08/2017. 24/08/2017. 30/08/2017. 01/09/2017. 04/09/2017. 08/09/2017. 14/09/2017.

Agenda - European Medicines Agency - Europa EU
Feb 9, 2018 - 30 Churchill Place ○ Canary Wharf ○ London E14 5EU ○ United Kingdom. An agency of the European Union ... product information. For information: Summary of opinion. 2.2. Oral explanations and list of outstanding issues. •. Product

Agenda - European Medicines Agency - Europa EU
Oct 23, 2017 - Page 2/61. Table of contents. 1. Introduction. 11. 1.1. Welcome and declarations of interest of members, alternates and experts .......... 11. 1.2. Agenda of the meeting on 23-26 October 2017 . ...... different database to study the ri

Evofosfamide - European Medicines Agency - Europa EU
Notification of discontinuation of a paediatric development which is covered by an agreed ... for the following reason(s): (tick all that apply). (possible) lack of ...

Agenda - European Medicines Agency - Europa EU
17 Jan 2018 - Expert meeting on adeno-associated viral vectors, 06 September 2017, EMA, London. CAT: Martina Schüßler-Lenz. Scope: report of the meeting that took place on 6 September 2017. Action: for adoption. 7.6.3. Environmental assessment of g

minoxidil - European Medicines Agency - Europa EU
Jun 14, 2018 - Page 2/26. Product Name (in authorisation country). MRP/DCP Authorisation number. National Authorisation. Number. MAH of product in the.

Influenza vaccine - European Medicines Agency - Europa EU
Oct 26, 2017 - Injektionssuspension in einer Fertigspritze. Influenza-Impfstoff. (Spaltimpfstoff, inaktiviert, in Zellkulturen hergestellt) not available. BE393556. NANOTHERAPEUTICS. BOHUMIL, S.R.O.. BE. Preflucel injektionsvätska, suspension i för

latanoprost - European Medicines Agency - Europa EU
May 13, 2016 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ..... Xaloptic Free. NL/H/3193/001.

Cyproterone/ethinylestradiol - European Medicines Agency - Europa EU
March 2016 a joint database drug utilisation final study report to the European .... With regards to prescription of CPA/EE for contraceptive management, ...

ganciclovir - European Medicines Agency - Europa EU
Feb 9, 2017 - Send a question via our website www.ema.europa.eu/contact. © European ... Product Name (in authorisation ... not available. 20010180.

July 2016 - European Medicines Agency - Europa EU
For a list of RSS readers please refer to our RSS guide and follow the instructions ..... PCWP and HCPWP joint meeting: Workshop on social media - Sep 2016.

Stem cell - European Medicines Agency - Europa EU
Jul 14, 2016 - Stem cell-based products for veterinary use: specific ... potentially delay time to rejection providing a window of therapeutic benefit but limiting ...